Pulmonary hypertension in interstitial lung disease: Clinical trial design and endpoints: A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative—Group 3 Pulmonary Hypertension-Reference-Cited by-同舟云学术

Pulmonary hypertension in interstitial lung disease: Clinical trial design and endpoints: A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative—Group 3 Pulmonary Hypertension

Published:2022-10 Issue:4 Volume:12 Page:
ISSN:2045-8940
Container-title:Pulmonary Circulation
language:en
Short-container-title:Pulm. circ.

Author:

Nathan Steven D.¹^ORCID,Fernandes Peter²,Psotka Mitchell³,Vitulo Patrizio⁴^ORCID,Piccari Lucilla⁵^ORCID,Antoniou Katerina⁶^ORCID,Nikkho Sylvia M.⁷^ORCID,Stockbridge Norman⁸

Affiliation:

1. Advanced Lung Disease and Transplant Program, Inova Heart and Vascular Institute Falls Church Virginia USA

2. Bellerophon Therapeutics Inc., Regulatory, Safety and Quality Department Warren New Jersey USA

3. Division of Cardiology and Nephrology, Food and Drug Administration Silver Spring Maryland USA

4. Department of Pulmonary Medicine, IRCCS Mediterranean Institute for Transplantation and Advanced Specialized, Therapies Palermo Sicilia Italy

5. Hospital del Mar, Pulmonary Hypertension Unit, Department of Pulmonary Medicine Barcelona Catalunya, ES Spain

6. University of Crete School of Medicine, Department of Thoracic Medicine Heraklion Crete Greece

7. Global Clinical Development, Bayer AG Berlin Germany

8. US Food and Drug Administration, Division of Cardiology and Nephrology Silver Spring Maryland USA

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pul2.12178

Reference53 articles.

1. Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's innovative drug development initiative—Group 3 pulmonary hypertension

2. A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ILOPROST INHALATION IN ADULTS WITH ABNORMAL PULMONARY ARTERIAL PRESSURE AND EXERCISE LIMITATION ASSOCIATED WITH IDIOPATHIC PULMONARY FIBROSIS

3. A Controlled Trial of Sildenafil in Advanced Idiopathic Pulmonary Fibrosis

4. Sildenafil Preserves Exercise Capacity in Patients With Idiopathic Pulmonary Fibrosis and Right-sided Ventricular Dysfunction

5. Bosentan in Pulmonary Hypertension Associated with Fibrotic Idiopathic Interstitial Pneumonia

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Group 5 Pulmonary Hypertension: Multiple Systemic Diseases, Multiple Mechanisms of Pulmonary Hypertension, and Multiple Management Challenges;Current Respiratory Medicine Reviews;2024-08

2. Cluster analysis identifies novel real-world lung disease-pulmonary hypertension sub-phenotypes: implications for treatment response;ERJ Open Research;2024-02-29

3. Use of inhaled treprostinil in patients with interstitial lung disease and pulmonary hypertension: to boldly go where no other pulmonary vasodilator has gone before?;Thorax;2024-02-02

4. Progress in the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease;American Journal of Respiratory and Critical Care Medicine;2023-08-01

5. Pulmonale Hypertonie bei Lungenerkrankungen;Herz;2023-04-27